SCHEMBL23356342

SCHEMBL23356342

CS(=O)(=O)c1cccc(NC(=O)c2cc3c(nc2Cl)CCC3)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 1/20 0.50
RXFP1 Q9HBX9 1/20 0.45
SMO Q99835 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA2B P29275 1/20 0.44
ADORA1 P30542 1/20 0.44
CSNK2A1 P68400 1/20 0.43
LMNA P02545 2/20 0.43
USP7 Q93009 1/20 0.42
BRAF P15056 1/20 0.42
SCN10A Q9Y5Y9 2/20 0.41
RAB9A P51151 3/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 3/20 0.41
NPC1 O15118 2/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31344050 1.00 MEN1 (0.50) MEN1KMT2AALDH1A1RXFP1SMO
SCHEMBL31344203 0.79 ALDH1A1 (0.55) MEN1KMT2AALDH1A1RXFP1SMO
SCHEMBL23356403 0.79 ALDH1A1 (0.55) MEN1KMT2AALDH1A1RXFP1SMO
SCHEMBL31344209 0.78 MEN1 (0.57) MEN1KMT2AALDH1A1RXFP1SMO
SCHEMBL23356353 0.78 MEN1 (0.57) MEN1KMT2AALDH1A1RXFP1SMO
SCHEMBL29618331 0.78 MEN1 (0.52) MEN1KMT2AALDH1A1ADORA3ADORA2A
SCHEMBL23356387 0.78 EGFR (0.57) MEN1KMT2AALDH1A1RXFP1SMO
SCHEMBL31344257 0.78 EGFR (0.57) MEN1KMT2AALDH1A1RXFP1SMO
SCHEMBL23356249 0.77 SCN10A (0.63) RXFP1LMNASCN10A
SCHEMBL31344134 0.77 SCN10A (0.63) RXFP1LMNASCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001861-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2026-01-01 US disclosed
US-12234221-B2 Pyridine carboxamide compounds for inhibiting NAV1.8 LIEBER INSTITUTE, INC. (US) 2025-02-25 US disclosed
US-20220227732-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2022-07-21 US disclosed
EP-3820866-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 Lieber Institute, Inc. (US) 2021-05-19 EP disclosed
CN-112689633-A For inhibiting Nav1.8 pyridine carboxamide Compounds 利伯研究所公司 2021-04-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220227732-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN1A, SCN2A MEN1 2933/4885KMT2A 1228/4885ALDH1A1 2945/4885
US-12234221-B2 Pyridine carboxamide compounds for inhibiting NAV1.8 SCN8A, SCN1A, SCN2A MEN1 2933/4885KMT2A 1228/4885ALDH1A1 2945/4885
US-20260001861-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN1A, SCN1B MEN1 3364/4885KMT2A 2792/4885ALDH1A1 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.